AstraZeneca says PREVAIL trial on gefurulimab met primary, secondary endpoints

Positive high-level results from a global, randomized, double-blind, placebo-controlled Phase III trial in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living, MG-ADL, total score at week 26 compared to placebo. Gefurulimab was well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors in gMG with no new safety signals observed. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.